- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
- Interventions
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
- Device · Drug
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 109
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pediatric Asthma, Critical Illness
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Colon Cancer
- Interventions
- PDT with 5-ALA radiosensitization
- Drug
- Lead sponsor
- Edward Nelson
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Orange, California • New York, New York
- Conditions
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- Interventions
- PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- dnaJ peptide, None-placebo
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Orange, California • Palo Alto, California + 5 more
- Conditions
- Covid19, Cytokine Storm, Inflammation
- Interventions
- Splenic ultrasound
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
- Interventions
- Extracorporeal Photopheresis (ECP), Methoxsalen
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Immunity
- Interventions
- An arginine rich nutritional supplement
- Dietary Supplement
- Lead sponsor
- Martin Angst
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Amputation, Traumatic, Amputation;Traumatic;Old, Face Injury, Face; Deformity, Abdominal Wall Defect
- Interventions
- IL-2
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19
- Interventions
- abatacept infusion, Placebo group
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
- Conditions
- Type 1 Diabetes
- Interventions
- DiaPep277®
- Drug
- Lead sponsor
- Andromeda Biotech Ltd.
- Industry
- Eligibility
- 18 Years to 47 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Asheville, North Carolina
- Conditions
- Dry Eye
- Interventions
- Cyclosporine, Artificial tear
- Drug
- Lead sponsor
- Vishal Jhanji
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
- Interventions
- Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
- Biological · Drug
- Lead sponsor
- Greater Atlanta Integrative Pediatrics
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Roswell, Georgia
- Conditions
- HIV Infections
- Interventions
- Thalidomide, Thalidomide placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV Infection
- Interventions
- DNA + HIV-rAd5 vaccine, ART intensification (raltegravir), ART intensification (maraviroc)
- Biological · Drug
- Lead sponsor
- Robert L. Murphy
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • New York, New York
- Conditions
- Surgery, Immune System and Related Disorders, Preoperative Care, Gastrointestinal Disease, Urological Disease, Gynecologic Disease, Thoracic Diseases
- Interventions
- Physical Prehabilitation, Stress Reduction Prehabilitation, Cognitive Prehabilitation, Nutrition Prehabilitation
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
- Interventions
- Dasatinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Kidney Transplantation, Renal Transplant Recipients
- Interventions
- Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infection
- Interventions
- Interleukin-2
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Interventions
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Drug
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Crohn's Disease, Vitamin D Deficiency
- Interventions
- Cholecalciferol
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
- Interventions
- Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
- Biological · Drug
- Lead sponsor
- Adia Med of Winter Park LLC
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Winter Park, Florida
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Sensoril®, Placebo
- Drug
- Lead sponsor
- K.N. Roy Chengappa
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois